Hims member benefits programme grows to 14 partners
- Good news: The programme grew from 2 partners to 14 in 8 months, mostly built around GLP-1 weight-loss subscribers, to help retention.
- Neutral: Hims earns nothing from it and passes 100% of the discounts to active subscribers, so it is not a revenue line.
- Bad news: It does little for the health data moat: Viome's test data stays with Viome.
Read the full notes
The membership benefits programme has grown from 2 partners to 14 in 8 months. Three of the 4 new partners are built around nutrition, muscle and body data during GLP-1 weight loss, so the programme is clearly aimed at weight-loss subscribers. It is not a revenue line, though:
Read more
Hims earns nothing from it and passes 100% of the discounts to active subscribers, so its role is limited to improving retention and cutting churn. It does little for the 'health data moat'. Viome's test data stays with Viome, the press release does not mention sharing data with Hims, and Hims' own data lines are still Labs blood draws and YourBio at-home collection. This is small product progress and does not change the core tension: revenue is growing, but gross margin and compliance costs are eroding earnings quality from both sides. The real test is the Q3 results on 9 Nov, in particular subscriber numbers and monthly revenue per user, above all retention in weight loss.
Key evidence
- 4 new partners: Grüns (nutrition gummies, $30 off the first order), Medjet (medical air-transport membership, about 30% off), Tonal (at-home smart strength trainer, $1,000 off the hardware), Viome (at-home RNA sequencing for the gut microbiome, $100 off) (company press release, 5 Nov)
- Pace: 2 partners at the March launch, 14 after 8 months
- 3 of the 4 are built around nutrition and muscle preservation during GLP-1 weight loss, as add-ons for weight-loss subscribers
- The press release says Hims earns nothing from the benefits and passes 100% of the discounts to active subscribers
- Viome's test data stays with Viome, and the press release does not mention sharing it with Hims
- Hims' own data lines are still Labs blood draws and YourBio at-home collection
- The remaining news is share-price moves, analyst consensus and law-firm solicitation for a class action (the same case reposted repeatedly), and there are no new SEC EDGAR filings since 30 Oct
Catalysts to watch
- Q3 results on 9 Nov: subscriber numbers, monthly revenue per user and weight-loss retention, which test whether the programme is working
- Further expansion of the programme (the pace has clearly picked up)
- Progress on Hims' own data lines, Labs and YourBio
Risks
- The core tension is unchanged: revenue is growing, but gross margin and compliance costs erode earnings quality from both sides
- The programme is a retention tool, not a revenue line, and cannot directly improve unit economics
- Health data moat: partners' data is not shared, and the pace at which Hims builds its own data is unchanged
- Class-action solicitation continues (the same case reposted by law firms, background noise)
Sources 3
- Hims company press release / Business Wire (5 Nov): 4 new partners join the membership benefits programme
- news.hims.com
- SEC EDGAR: no new filings since 30 Oct